View Older Stories View More Recent Stories

Sep 20, 2021 09:10AM AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's Disease
Sep 16, 2021 08:01AM AbbVie (ABBV) Submits Applications to FDA and EMA for Upadacitinib for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
Sep 16, 2021 08:00AM AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
Sep 13, 2021 07:26AM AbbVie (ABBV) and REGENXBIO (RGNX) Announce Eye Care Collaboration
Sep 13, 2021 06:30AM AbbVie and REGENXBIO Announce Eye Care Collaboration
Sep 10, 2021 10:27AM AbbVie Declares Quarterly Dividend
Sep 10, 2021 09:00AM AbbVie to Highlight Its Leadership in Movement Disorders at the International Parkinson and Movement Disorder Society Virtual Congress 2021
Sep 9, 2021 08:00AM AbbVie to Present at the Morgan Stanley Healthcare Conference
Sep 9, 2021 07:00AM Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet
Sep 9, 2021 07:00AM Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet
Sep 9, 2021 07:00AM Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL) Published in The Lancet
Sep 8, 2021 09:10AM AbbVie to Present Data From Its Migraine Portfolio at the 2021 International Headache Congress
Aug 24, 2021 08:02AM AbbVie (ABBV) Announces European Approval of RINVOQ® as First JAK Inhibitor the Treatment of Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Aug 24, 2021 08:00AM European Commission Approves RINVOQ® (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Aug 18, 2021 05:29PM AbbVie (ABBV) Announces NEJM Publishes 12-Week Results from Study Evaluating Atogepant for the Preventive Treatment of Migraine
Aug 18, 2021 05:28PM New England Journal of Medicine Publishes 12-Week Results from Study Evaluating Atogepant for the Preventive Treatment of Migraine
Aug 9, 2021 08:45AM AbbVie (ABBV) Announces SKYRIZI Now Available in the U.S. as a Single 150 mg Injection for Adults with Moderate to Severe Plaque Psoriasis
Aug 9, 2021 08:45AM SKYRIZI® (risankizumab-rzaa) Now Available in the U.S. as a Single 150 mg Injection for Adults with Moderate to Severe Plaque Psoriasis
Aug 9, 2021 04:00AM Mission and AbbVie Collaboration in Alzheimer’s and Parkinson’s Diseases Reaches Next Milestone
Aug 4, 2021 12:02PM AbbVie (ABBV) Announces JAMA Dermatology Publishes Data Showing RINVOQ Achieved Superiority Vs DUPIXENT in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis
Aug 4, 2021 12:01PM JAMA Dermatology Publishes Data Showing RINVOQ® (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) for Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adul
Jul 30, 2021 07:44AM AbbVie Reports Second-Quarter 2021 Financial Results
Jul 29, 2021 08:36AM AbbVie (ABBV) Announces FDA Approves Expanded BOTOX Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity
Jul 29, 2021 08:30AM FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity
Jul 27, 2021 08:32AM AbbVie (ABBV), Calico Announce Second Extension of Collaboration Focused on Aging and Age-Related Diseases
Jul 27, 2021 08:30AM AbbVie and Calico Announce Second Extension of Collaboration Focused on Aging and Age-Related Diseases
Jul 26, 2021 05:36AM AbbVie (ABBV) AGN-190584 Meets Both Primary and Secondary Endpoints
Jul 25, 2021 11:31AM New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition
Jul 23, 2021 12:38PM AbbVie (ABBV) Announces DALVANCE Receives FDA Approval to Treat Acute Bacterial Skin and Skin Structure Infections in Pediatric Patients
Jul 23, 2021 12:37PM DALVANCE® (dalbavancin) Receives FDA Approval to Treat Acute Bacterial Skin and Skin Structure Infections in Pediatric Patients
Jul 21, 2021 06:13AM AbbVie (ABBV) Announces Venetoclax Granted US FDA Breakthrough Therapy Designation in Higher Risk Myelodysplastic Syndrome
Jul 21, 2021 01:00AM Venetoclax (VENCLEXTA®) Granted US FDA Breakthrough Therapy Designation (BTD) in Higher Risk Myelodysplastic Syndrome (MDS)
Jul 20, 2021 08:35AM AbbVie's (ABBV) Allergan to Present New Data from its Leading Eye Care Portfolio at the 2021 ASCRS Annual Meeting
Jul 20, 2021 08:30AM Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the 2021 ASCRS (American Society of Cataract and Refractive Surgery) Annual Meeting
Jul 16, 2021 08:32AM AbbVie (ABBV) Provides Update Regarding RINVOQ for Treatment of Moderate to Severe Atopic Dermatitis in the U.S.
Jul 16, 2021 08:30AM AbbVie Provides Update Regarding RINVOQ® (upadacitinib) for the Treatment of Moderate to Severe Atopic Dermatitis in the U.S.
Jul 8, 2021 04:06PM Collaboration Between AbbVie, Biogen and Pfizer Creates World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease
Jul 8, 2021 04:06PM Collaboration Between AbbVie, Biogen and Pfizer Creates World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease
Jul 7, 2021 08:00AM AbbVie to Host Second-Quarter 2021 Earnings Conference Call
Jun 29, 2021 08:01AM AbbVie (ABBV) Announces Upadacitinib Met Primary and All Secondary Endpoints in the 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients
Jun 29, 2021 08:00AM Upadacitinib (RINVOQ®) Met the Primary and All Secondary Endpoints in the 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients
Jun 28, 2021 08:45AM AbbVie Gastroenterology Pipeline to be Featured at the 16th Congress of European Crohn's and Colitis Organisation (ECCO)
Jun 25, 2021 08:35AM AbbVie (ABBV) Announces FDA Will Not Meet PDUFA Action Dates for RINVOQ sNDAs
Jun 25, 2021 08:30AM AbbVie Provides Update Regarding RINVOQ® (upadacitinib) in Psoriatic Arthritis and Ankylosing Spondylitis in the U.S.
Jun 25, 2021 06:15AM AbbVie (ABBV) Announces CHMP Recommends Approval of RINVOQ (upadacitinib) for the Treatment of Atopic Dermatitis
Jun 25, 2021 02:30AM CHMP Recommends Approval of RINVOQ® (upadacitinib) for the Treatment of Atopic Dermatitis
Jun 24, 2021 08:02AM Alpine Immune Sciences (ALPN) Doses First Patient in Synergy, ALPN-101 Phase 2 Lupus Clinical Trial, $45M Milestone Achieved
Jun 24, 2021 08:01AM AbbVie (ABBV) Exercises Option to Acquire TeneoOne
Jun 24, 2021 08:00AM AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma
Jun 17, 2021 06:29PM AbbVie Declares Quarterly Dividend
View More Recent Stories View Older Stories